Javascript must be enabled to continue!
Perceived Social Support of HIV/AIDS Orphans
View through CrossRef
The present study examined the group and gender deference in Perceived social support (PSS) on a sample of HIV/AIDS orphans and non- HIV/AIDS orphans. The sample of the study consisted of 236 orphans (116 HIV/AIDS orphans and 120 non- HIV/AIDS orphans) the mean age of HIV/AIDS orphans, 11.66 years and mean age of non-HIV/AIDS orphans, 11.78 years living in the north Indian orphanages. The tools employed for present study is PSS scale for children consisting of 30 items and comprising of three subscales assessing the source of the emotional support (i.e., family, friends, or teacher). Result related to MANOVA indicates that significant group difference (F=2.66, p<0.05) and significant gender difference (F=2.66, p<0.05) was found in HIV/AIDS orphans and non-HIV/AIDS orphans on perceived social support. The present research explored low PSS of HIV/AIDS orphans living in Indian orphanages. PSS plays a protective role in dealing with psychosocial outcomes of HIV/AIDS orphans. Strong perception of support from cares, siblings, school teachers, school principal, friends, and others may reduce the deleterious effects of exposure to illness and psychological problems.
Title: Perceived Social Support of HIV/AIDS Orphans
Description:
The present study examined the group and gender deference in Perceived social support (PSS) on a sample of HIV/AIDS orphans and non- HIV/AIDS orphans.
The sample of the study consisted of 236 orphans (116 HIV/AIDS orphans and 120 non- HIV/AIDS orphans) the mean age of HIV/AIDS orphans, 11.
66 years and mean age of non-HIV/AIDS orphans, 11.
78 years living in the north Indian orphanages.
The tools employed for present study is PSS scale for children consisting of 30 items and comprising of three subscales assessing the source of the emotional support (i.
e.
, family, friends, or teacher).
Result related to MANOVA indicates that significant group difference (F=2.
66, p<0.
05) and significant gender difference (F=2.
66, p<0.
05) was found in HIV/AIDS orphans and non-HIV/AIDS orphans on perceived social support.
The present research explored low PSS of HIV/AIDS orphans living in Indian orphanages.
PSS plays a protective role in dealing with psychosocial outcomes of HIV/AIDS orphans.
Strong perception of support from cares, siblings, school teachers, school principal, friends, and others may reduce the deleterious effects of exposure to illness and psychological problems.
Related Results
HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
OSPHL in collaboration with APHL, will evaluate the performance of the Oxford Nanopore Technology sequencers for HIV genome sequencing using a modified protocol of the ARTIC amplic...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
Evaluasi peningkatan pengetahuan tentang HIV/AIDS dan sikap terhadap ODHA di SMK Gelora Jaya Nusantara
Evaluasi peningkatan pengetahuan tentang HIV/AIDS dan sikap terhadap ODHA di SMK Gelora Jaya Nusantara
Background: HIV/AIDS remains a global health problem in Indonesia, with major barriers being misunderstandings, social stigma, and ineffective educational approaches. The level of ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...

